This author has yet to write their bio.Meanwhile lets just say that we are proud admin contributed a whooping 71 entries.
Entries by admin
Our paper is out in Frontiers in PharmacologyApril 23, 2022 /0 Comments/in Blog /by admin
Our paper on first ever reported establishment of a cell culture from a rare brain tumor (DIG glioma), is published in Frontiers in Pharmacology journal, with Impact factor of 4.5. Such primary cultures are very useful for drugdevelopment and phenotypic screening.
Sapien’s work for Hillstream BioPharma presented at AACRApril 20, 2022 /0 Comments/in Blog /by admin
Sapien biobank evaluates novel drug candidates and formulations for global biotech and pharma companies using our proprietary panel of live cells and 3Dcellculture derived from cancer surgeries tissues. These are also called patient-derived cells or PDCs. Assays using PDCs are very valuable before going to clinical trials. We are delighted that our work done with […]
Dr. Jugnu Jain shares her thoughts on entrepreneurship with the T-Hub HyderabadMarch 25, 2022 /0 Comments/in Blog /by admin
Landscape of Kinase gene fusions in cancersDecember 30, 2021 /0 Comments/in Blog /by admin
Tyrosine kinases such as ALK, RET and ROS1 are often activated by translocations or chromosomal rearrangements that result in increased oncogenic activity and are attractive candidates for targeted therapy. In our #biobank, we have identified many patient samples harbouring ALK, RET and ROS1 rearrangements by NGS. FDA approved drugs such as Crizotinib (Xalkori, #Pfizer), Ceritinib […]
ALK targeted therapy for lung cancer: Integration of NGS genome profiling in management of ALK-mutated NSCLCs in IndiaNovember 27, 2021 /0 Comments/in Blog /by admin
The NGS genotyping of our NSCLC cases using ThermoFisher’s Oncomine panel identified 8 genetic variants in the ALK gene in 9 cases (16.67%), some of which, such as G1202R and S1206Y surprisingly confer resistance to #Crizotinib treatment, but demonstrate sensitivity to second-generation ALK inhibitors such as #Brigatinib and #Ceritinib, which are currently approved for the […]
Building Genotype-Phenotype Correlation Data for Lung Cancer in IndiaNovember 18, 2021 /0 Comments/in Blog /by admin
Sapien is curating real world data for the lung cancer cases in the biobank. While 90-95% of our NSCLC samples are biopsies which are mostly exhausted in patient diagnosis and subsequent clinical #biomarker evaluation, the resection samples are being characterized genomically in Oncomine panel to correlate the demographic, diagnostic, treatment and outcomes data with genetic […]
KRAS mutations in Breast cancer may be treatableOctober 13, 2021 /0 Comments/in Blog /by admin
For decades, mutations in #KRAS have been known to cause cancers in multiple organs and the gene KRAS itself was considered ‘undruggable’. Of the many mutations, KRAS-G12C is known to occur in nearly 13% of #NSCLC cases. There were no known treatments that can target KRAS-G12C mutation until recently. May 2021 heralded the #fdaapproval of […]
1st Floor, AIMSR Building,
Apollo Health City,
Hyderabad 500 096
- Digital library of whole slide Images Built at Sapien
- Dr. Jugnu Jain, CEO, delivering an invited talk on “Sustainability of Biobanking in India” at the workshop on Biobanking organized by ILBS, New Delhi.
- Quatramer’s tunability stems from the fact that the system can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms of action in lower doses.
- Our paper is out in Frontiers in Pharmacology
- Sapien’s work for Hillstream BioPharma presented at AACR